02162 PE Ratio & Valuation, Is 02162 Overvalued

Historical Valuation

KEYMED BIO-B (02162) is now in the Fair zone, suggesting that its current forward PS ratio of 16.36 is considered Fairly compared with the five-year average of -21.51. The fair price of KEYMED BIO-B (02162) is between 0.58 to 289.11 according to relative valuation method.

Relative Value

Fair Zone

0.58-289.11

Current Price：52.40

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is KEYMED BIO-B (02162) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

KEYMED BIO-B (02162) has a current Price-to-Book (P/B) ratio of 4.64. Compared to its 3-year average P/B ratio of 4.09, the current P/B ratio is approximately 13.66% higher. Relative to its 5-year average P/B ratio of 3.37, the current P/B ratio is about 37.91% higher. KEYMED BIO-B (02162) has a Forward Free Cash Flow (FCF) yield of approximately -6.05%. Compared to its 3-year average FCF yield of -7.29%, the current FCF yield is approximately -17.02% lower. Relative to its 5-year average FCF yield of -6.57%, the current FCF yield is about -7.99% lower.

Performance Decomposition

AI Analysis

Market capitalization of 02162 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 02162 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 02162 currently overvalued or undervalued?

What is KEYMED BIO-B (02162) fair value?

02162's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of KEYMED BIO-B (02162) is between 0.58 to 289.11 according to relative valuation method.

How does 02162's valuation metrics compare to the industry average?

The average P/S ratio for 02162's competitors is 0.00, providing a benchmark for relative valuation. KEYMED BIO-B Corp (02162) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for KEYMED BIO-B (02162) as of Mar 06 2026?

As of Mar 06 2026, KEYMED BIO-B (02162) has a P/B ratio of 4.64. This indicates that the market values 02162 at 4.64 times its book value.

What is the current FCF Yield for KEYMED BIO-B (02162) as of Mar 06 2026?

As of Mar 06 2026, KEYMED BIO-B (02162) has a FCF Yield of -6.05%. This means that for every dollar of KEYMED BIO-B's market capitalization, the company generates -6.05 cents in free cash flow.

What is the current Forward P/E ratio for KEYMED BIO-B (02162) as of Mar 06 2026?

As of Mar 06 2026, KEYMED BIO-B (02162) has a Forward P/E ratio of -24.45. This means the market is willing to pay $-24.45 for every dollar of KEYMED BIO-B's expected earnings over the next 12 months.

What is the current Forward P/S ratio for KEYMED BIO-B (02162) as of Mar 06 2026?

As of Mar 06 2026, KEYMED BIO-B (02162) has a Forward P/S ratio of 16.36. This means the market is valuing 02162 at $16.36 for every dollar of expected revenue over the next 12 months.

02162 Valuation